Efficacy, Safety and Pharmacokinetics of Different Regimens of Indacaterol

PHASE2CompletedINTERVENTIONAL
Enrollment

191

Participants

Timeline

Start Date

March 31, 2010

Primary Completion Date

July 31, 2010

Conditions
Persistent Asthma
Interventions
DRUG

Indacaterol

Indacaterol inhaled via Concept1, a single dose dry powder inhaler (SDDPI) for 16 days. Dosage and frequency varied according to randomization scheme.

DRUG

Placebo to Indacaterol

Placebo inhaled via Concept1, a SDDPI. Frequency varied according to randomization scheme.

Trial Locations (30)

27607

Novartis Investigative Site, Raleigh

33167

Novartis Investigative Site, Miami

33175

Novartis Investigative Site, Miami

33617

Novartis Investigative Site, Tampa

33756

Novartis Investigative Site, Clearwater

34233

Novartis Investigative Site, Sarasota

36207

Novartis Investigative Site, Anniston

61761

Novartis Investigative Site, Normal

70503

Novartis Investigative Site, Lafayette

73120

Novartis Investigator Site, Oklahoma City

75075

Novartis Investigative Site, Plano

77070

Novartis Investigative Site, Houston

78212

Novartis Investigative Site, San Antonio

80206

Novartis Investigative Site, Denver

89119

Novartis Investigative Site, Las Vegas

90630

Novartis Investigative Site, Cypress

92120

Novartis Investigative Site, San Diego

93726

Novartis Investigative Site, Fresno

98405

Novartis Investigative Site, Tacoma

98418

Novartis Investigative Site, Tacoma

08009

Novartis Investigative Site, Berlin

Unknown

Novartis Investigative Site, Paris

Novartis Investigative Site, Rennes

Novartis Investigative Site, Wiesbaden

Novartis Investigative Site, Amman

Novartis Investigative Site, Irbid

Novartis Investigative Site, Groningen

Novartis Investigative Site, London

Novartis Investigative Site, Manchester

Novartis Investigative Site, Merthyr Tydfil

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY